These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30261755)

  • 1. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rinaldi B; Page C; Rogliani P; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1101-1111. PubMed ID: 30261755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB; Kanner RE
    Drugs Aging; 2007; 24(8):615-28. PubMed ID: 17702532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future of chronic obstructive pulmonary disease management.
    D'Urzo A; Vogelmeier C
    Expert Rev Respir Med; 2012 Jun; 6(3):285-99. PubMed ID: 22788943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchodilators use in patients with COPD.
    Dong YH; Hsu CL; Li YY; Chang CH; Lai MS
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1769-79. PubMed ID: 26366069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on bronchodilators in Phase I and II clinical trials.
    Cazzola M; Rogliani P; Segreti A; Matera MG
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1489-501. PubMed ID: 22916733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
    Monaco TJ; Hanania NA
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):285-299. PubMed ID: 28868931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N
    Pecchiari M; Santus P; Radovanovic D; DʼAngelo E
    J Appl Physiol (1985); 2017 Nov; 123(5):1266-1275. PubMed ID: 28775071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of indacaterol for the treatment of COPD.
    Metaxas EI; Balis E
    Expert Opin Drug Saf; 2018 Jun; 17(6):637-642. PubMed ID: 29741108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.
    Cazzola M; Beeh KM; Price D; Roche N
    Pulm Pharmacol Ther; 2015 Apr; 31():68-78. PubMed ID: 25727846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and therapeutics of bronchodilators.
    Cazzola M; Page CP; Calzetta L; Matera MG
    Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence.
    Aggarwal B; Gogtay J
    Expert Rev Respir Med; 2014 Jun; 8(3):349-56. PubMed ID: 24802511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.